DK3551209T3 - Insulin-fc-fusioner og fremgangsmåder til anvendelse - Google Patents
Insulin-fc-fusioner og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK3551209T3 DK3551209T3 DK17878116.7T DK17878116T DK3551209T3 DK 3551209 T3 DK3551209 T3 DK 3551209T3 DK 17878116 T DK17878116 T DK 17878116T DK 3551209 T3 DK3551209 T3 DK 3551209T3
- Authority
- DK
- Denmark
- Prior art keywords
- mergers
- insulin
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432268P | 2016-12-09 | 2016-12-09 | |
| US201762514449P | 2017-06-02 | 2017-06-02 | |
| US201762514460P | 2017-06-02 | 2017-06-02 | |
| US201762514427P | 2017-06-02 | 2017-06-02 | |
| PCT/US2017/065456 WO2018107117A1 (en) | 2016-12-09 | 2017-12-08 | Insulin-fc fusions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3551209T3 true DK3551209T3 (da) | 2021-08-23 |
Family
ID=62491387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17878116.7T DK3551209T3 (da) | 2016-12-09 | 2017-12-08 | Insulin-fc-fusioner og fremgangsmåder til anvendelse |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11359001B2 (da) |
| EP (2) | EP3551209B1 (da) |
| JP (2) | JP7170332B2 (da) |
| CN (1) | CN110612112B (da) |
| AU (2) | AU2017371217B2 (da) |
| BR (1) | BR112019011860A2 (da) |
| CA (1) | CA3046337C (da) |
| DK (1) | DK3551209T3 (da) |
| HR (1) | HRP20211334T1 (da) |
| HU (1) | HUE055417T2 (da) |
| LT (1) | LT3551209T (da) |
| SI (1) | SI3551209T1 (da) |
| WO (1) | WO2018107117A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612112B (zh) | 2016-12-09 | 2024-03-29 | 阿卡斯通生物科学公司 | 胰岛素-fc融合物及使用方法 |
| DK4186920T5 (da) | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3122636A1 (en) * | 2018-12-11 | 2020-06-18 | Sanofi | Insulin analogs having reduced insulin receptor binding affinity |
| WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| KR102865175B1 (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| BR112022020486A2 (pt) | 2020-04-10 | 2023-01-17 | Akston Biosciences Corp | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| WO2022017309A1 (zh) * | 2020-07-24 | 2022-01-27 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
| WO2023004406A2 (en) * | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| CN115894720B (zh) * | 2023-01-16 | 2024-07-09 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
| US12416020B2 (en) * | 2024-02-20 | 2025-09-16 | Wyvern Pharmaceuticals Inc. | Plasmid encoding a TLR3 and Fc fusion protein |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPH07116160B2 (ja) | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性ｌ−カルノシン亜鉛錯体およびその製造法 |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
| US20030040601A1 (en) * | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
| US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| EP2413969A4 (en) | 2009-03-30 | 2012-09-05 | Boehringer Ingelheim Int | FUSION PROTEINS WITH DOG FC ELEMENTS |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| AU2011282977A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| AU2012271361B2 (en) * | 2011-06-17 | 2017-03-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| WO2013074598A1 (en) | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| BR112015019985A2 (pt) | 2013-02-26 | 2017-08-29 | Hanmi Pharm Ind Co Ltd | Novo análogo de insulina e sua utilização |
| WO2016044676A2 (en) | 2014-09-18 | 2016-03-24 | AskGene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| CA2975017A1 (en) | 2015-01-29 | 2016-08-04 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| JP2018508504A (ja) | 2015-02-17 | 2018-03-29 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続型インスリンまたはインスリンアナログ結合体 |
| JP6738831B2 (ja) | 2015-05-04 | 2020-08-12 | アポジェニックス アーゲー | 単鎖ｃｄ４０受容体アゴニストタンパク質 |
| AR105616A1 (es) * | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| WO2016193380A1 (en) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| CN114835797A (zh) | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| CN110612112B (zh) | 2016-12-09 | 2024-03-29 | 阿卡斯通生物科学公司 | 胰岛素-fc融合物及使用方法 |
| US11174303B2 (en) | 2017-03-07 | 2021-11-16 | Case Western Reserve University | Single-chain insulin analogues stabilized by a fourth disulfide bridge |
| CN119390821A (zh) | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| CN112423741A (zh) | 2018-04-16 | 2021-02-26 | 犹他大学研究基金会 | 葡萄糖反应性胰岛素 |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| DK4186920T5 (da) | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| CA3114395A1 (en) | 2018-09-25 | 2020-04-02 | Absci, Llc | Protein purification methods |
| TW202028229A (zh) | 2018-10-05 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 包含胰島素肽及ｅｇｆ（ａ）肽之雙功能化合物 |
| US20220002373A1 (en) | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
| WO2020236762A2 (en) | 2019-05-17 | 2020-11-26 | Case Western Reserve University | Variant single-chain insulin analogues |
| WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2017
- 2017-12-08 CN CN201780085106.8A patent/CN110612112B/zh active Active
- 2017-12-08 DK DK17878116.7T patent/DK3551209T3/da active
- 2017-12-08 US US16/468,182 patent/US11359001B2/en active Active
- 2017-12-08 HR HRP20211334TT patent/HRP20211334T1/hr unknown
- 2017-12-08 EP EP17878116.7A patent/EP3551209B1/en active Active
- 2017-12-08 LT LTEPPCT/US2017/065456T patent/LT3551209T/lt unknown
- 2017-12-08 SI SI201730909T patent/SI3551209T1/sl unknown
- 2017-12-08 BR BR112019011860A patent/BR112019011860A2/pt unknown
- 2017-12-08 WO PCT/US2017/065456 patent/WO2018107117A1/en not_active Ceased
- 2017-12-08 JP JP2019551507A patent/JP7170332B2/ja active Active
- 2017-12-08 EP EP21181286.2A patent/EP3939605A1/en active Pending
- 2017-12-08 CA CA3046337A patent/CA3046337C/en active Active
- 2017-12-08 AU AU2017371217A patent/AU2017371217B2/en active Active
- 2017-12-08 HU HUE17878116A patent/HUE055417T2/hu unknown
-
2019
- 2019-06-12 US US16/438,681 patent/US10597435B2/en active Active
-
2020
- 2020-08-31 AU AU2020227002A patent/AU2020227002B2/en active Active
-
2022
- 2022-10-25 JP JP2022170351A patent/JP7614655B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200131243A1 (en) | 2020-04-30 |
| JP2023017806A (ja) | 2023-02-07 |
| US11359001B2 (en) | 2022-06-14 |
| EP3939605A1 (en) | 2022-01-19 |
| WO2018107117A1 (en) | 2018-06-14 |
| US20190315828A1 (en) | 2019-10-17 |
| JP7614655B2 (ja) | 2025-01-16 |
| HRP20211334T1 (hr) | 2021-11-26 |
| JP7170332B2 (ja) | 2022-11-14 |
| EP3551209A1 (en) | 2019-10-16 |
| CN110612112A (zh) | 2019-12-24 |
| EP3551209A4 (en) | 2020-06-03 |
| LT3551209T (lt) | 2021-09-10 |
| CN110612112B (zh) | 2024-03-29 |
| BR112019011860A2 (pt) | 2019-11-12 |
| AU2017371217B2 (en) | 2020-03-19 |
| HUE055417T2 (hu) | 2021-11-29 |
| US10597435B2 (en) | 2020-03-24 |
| EP3551209B1 (en) | 2021-06-30 |
| CA3046337C (en) | 2021-06-01 |
| SI3551209T1 (sl) | 2021-10-29 |
| AU2020227002B2 (en) | 2024-02-01 |
| CA3046337A1 (en) | 2018-06-14 |
| AU2020227002A1 (en) | 2020-09-17 |
| AU2017371217A1 (en) | 2019-07-25 |
| JP2020503889A (ja) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| DK3551209T3 (da) | Insulin-fc-fusioner og fremgangsmåder til anvendelse | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3529257T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK4105223T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3601358T5 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3464282T3 (da) | Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3515478T3 (da) | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3474996T3 (da) | Tågeapparat og anvendelsesmåde | |
| DK3387438T3 (da) | Mikrofluidiske indretninger og kits samt fremgangsmåder til anvendelse heraf | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf |